Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 6:27 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 841–864 of 50,341 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Neoplasms Clear all
Recruiting Not applicable Interventional

Tools for Reducing Inequity in Acute Leukemia (TRIAL): Beta Testing

NCT06907797
View directory record Official record
Conditions
Acute Leukemia, Leukemia
Interventions
TRIAL Web-Based Application
Behavioral
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 28, 2026, 6:27 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

A Study of HST-1011 Given as Monotherapy and in Combination With an Anti-PD1 Antibody

NCT05662397
View directory record Official record
Conditions
Solid Tumor, Adult, Relapsed Cancer, Refractory Cancer
Interventions
HST-1011, Cemiplimab
Drug · Biological
Lead sponsor
HotSpot Therapeutics, Inc
Industry
Eligibility
18 Years and older
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
8
States / cities
Sarasota, Florida • Las Vegas, Nevada • New York, New York + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2025 · Synced Oct 28, 2026, 6:27 AM EDT
Completed Phase 2 Interventional

S9926 Temozolomide in Patients With Unresectable/Metastatic Gastrointestinal Stromal Tumors

NCT00005597
View directory record Official record
Conditions
Gastrointestinal Stromal Tumor
Interventions
temozolomide
Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2005
U.S. locations
106
States / cities
Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 67 more
Source: ClinicalTrials.gov public record
Updated Jan 3, 2013 · Synced Oct 28, 2026, 6:27 AM EDT
Recruiting Phase 3 Interventional

Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer

NCT05946213
View directory record Official record
Conditions
Prostate Adenocarcinoma, Stage III Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8
Interventions
Biospecimen Collection, Bone Scan, Computed Tomography, External Beam Radiation Therapy, Magnetic Resonance Imaging, Positron Emission Tomography, Quality-of-Life Assessment, Questionnaire Administration, Stereotactic Body Radiation Therapy
Procedure · Radiation · Other
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older · Male only
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2041
U.S. locations
424
States / cities
Birmingham, Alabama • Tuscaloosa, Alabama • Little Rock, Arkansas + 318 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Oct 28, 2026, 6:27 AM EDT
Recruiting No phase listed Observational

Upright MRI for Prostate Cancer Screening

NCT03474913
View directory record Official record
Conditions
Prostate Cancer, Elevated PSA, Elevated Prostate Specific Antigen
Interventions
Upright MRI, Standard MRI
Device
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years to 100 Years · Male only
Enrollment
550 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 7, 2026 · Synced Oct 28, 2026, 6:27 AM EDT
Not listed Phase 1Phase 2 Interventional

Magnetic Resonance Imaging-Guided Laser Induced Thermal Therapy for Treatment of Metastatic Brain Tumors

NCT00787982
View directory record Official record
Conditions
Brain Neoplasms
Interventions
MRI-Guided Laser Induced Thermal Therapy
Device
Lead sponsor
Visualase, Inc.
Industry
Eligibility
Not listed
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Manhasset, New York
Source: ClinicalTrials.gov public record
Updated Jan 1, 2010 · Synced Oct 28, 2026, 6:27 AM EDT
Completed Not applicable Interventional Results available

Endoesophageal Brachytherapy for Patients With Esophageal Cancer

NCT03335813
View directory record Official record
Conditions
Esophageal Cancer
Interventions
Endoesophageal Brachytherapy
Device
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Weston, Florida
Source: ClinicalTrials.gov public record
Updated Jun 9, 2022 · Synced Oct 28, 2026, 6:27 AM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers

Does Moderate Intensity Exercise Help Prevent Smoking Relapse Among Women?

NCT00420160
View directory record Official record
Conditions
Lung Cancer, Heart Disease, COPD
Interventions
Smoking cessation treatment plus moderate intensity exercise, Smoking cessation treatment plus health education
Behavioral
Lead sponsor
The Miriam Hospital
Other
Eligibility
18 Years to 65 Years · Female only
Enrollment
59 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Apr 14, 2015 · Synced Oct 28, 2026, 6:27 AM EDT
Withdrawn Phase 3 Interventional

Phase 3 Study of Levulan With New Blue Light for AK on the Face or Scalp

NCT03024060
View directory record Official record
Conditions
Actinic Keratosis
Interventions
ALA, Vehicle, IBL 20 mW, IBL 10 mW
Drug · Device
Lead sponsor
DUSA Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
7
States / cities
San Diego, California • Arlington Heights, Illinois • Carmel, Indiana + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2017 · Synced Oct 28, 2026, 6:27 AM EDT
Terminated Phase 2 Interventional

High-Dose Esterified Estrogens in Treating Postmenopausal Women With Metastatic Breast Cancer That Has Failed Previous Hormone Therapy

NCT00131924
View directory record Official record
Conditions
Breast Cancer
Interventions
esterified estrogens
Biological
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older · Female only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 11, 2012 · Synced Oct 28, 2026, 6:27 AM EDT
Completed Phase 2 Interventional Results available

Azacitidine in Treating Patients With Previously Treated Advanced Non-Small Cell Lung Cancer

NCT01281124
View directory record Official record
Conditions
Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Non-Small Cell Cancer AJCC v7
Interventions
Azacitidine, Diagnostic Laboratory Biomarker Analysis, Pharmacological Study
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 24, 2019 · Synced Oct 28, 2026, 6:27 AM EDT
Completed Not applicable Interventional

Individualized Exercise Programs for Patients Receiving Chemotherapy for Newly Diagnosed Acute or Relapsed Myeloid Leukemia or Lymphoblastic Leukemia

NCT00499759
View directory record Official record
Conditions
Depression, Fatigue, Leukemia, Musculoskeletal Complications, Psychosocial Effects of Cancer and Its Treatment
Interventions
Resting vitals, Body Composition, Timed Get-up and Go test (TGUG)., Cardiorespiratory assessment, Handgrip evaluation, Dynamic muscular endurance
Behavioral
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years to 60 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 6, 2012 · Synced Oct 28, 2026, 6:27 AM EDT
Completed Phase 1Phase 2 Interventional

Combination Study of a New Taxane and Capecitabine in Patients With Metastatic Breast Cancer

NCT00327743
View directory record Official record
Conditions
Breast Cancer, Cancer
Interventions
larotaxel, capecitabine
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older · Female only
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated May 18, 2016 · Synced Oct 28, 2026, 6:27 AM EDT
Active, not recruiting Phase 1 Interventional

A Study of Nivolumab and Chemotherapy Followed by Surgery for Mesothelioma

NCT04162015
View directory record Official record
Conditions
Malignant Pleural Mesothelioma
Interventions
Nivolumab, Pemetrexed, Cisplatin or Carboplatin
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 28, 2026, 6:27 AM EDT
Completed Not applicable Interventional Results available

Evaluating Impact of NIRAF Detection for Identifying Parathyroid Glands During Parathyroidectomy

NCT04299425
View directory record Official record
Conditions
Parathyroid Adenoma, Parathyroid Neoplasms, Parathyroid Hyperplasia, Parathyroid Cancer, Hypercalcemia, Primary Hyperparathyroidism
Interventions
NIRAF Detection Technology
Device
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years to 99 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 13, 2024 · Synced Oct 28, 2026, 6:27 AM EDT
Completed Phase 1Phase 2 Interventional

Phase I/II Study of Escalating-Dose Melphalan w/Autologous SCS & Amifostine Cytoprotect

NCT00003425
View directory record Official record
Conditions
Breast Cancer, Leukemia, Lymphoma, Neuroblastoma, Ovarian Cancer, Sarcoma, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
filgrastim, amifostine trihydrate, cyclophosphamide, melphalan, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
University of Kentucky
Other
Eligibility
14 Years to 70 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1997
U.S. locations
4
States / cities
Lexington, Kentucky • Baltimore, Maryland • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2013 · Synced Oct 28, 2026, 6:27 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Unidos Contra el VPH

NCT06825689
View directory record Official record
Conditions
Human Papilloma Virus (HPV), Cervical Cancers
Interventions
Self-sampling with urine, Self-sampling with swab, In-clinic Pap/HPV co-testing
Device
Lead sponsor
University of Texas at Austin
Other
Eligibility
30 Years to 65 Years · Female only
Enrollment
735 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2029
U.S. locations
1
States / cities
El Paso, Texas
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Oct 28, 2026, 6:27 AM EDT
Recruiting Phase 2 Interventional

A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation.

NCT05967689
View directory record Official record
Conditions
Advanced or Metastatic NSCLC Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations
Interventions
TAS6417, CYP Cocktail, Transporter Cocktail
Drug
Lead sponsor
Taiho Oncology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
18
States / cities
Birmingham, Alabama • Duarte, California • Boston, Massachusetts + 15 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 28, 2026, 6:27 AM EDT
Completed Not applicable Interventional Results available

High- Fiber/ Low-fat Diet for Prevention of Recurrent Clostridioides Difficile Infection in Oncology

NCT04940468
View directory record Official record
Conditions
Leukemia, Lymphocytic, Acute, Leukemia, Myeloid, Acute, Lymphoma, Clostridium Difficile Infection, Solid Cancers
Interventions
Diet Intervention
Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
9 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
2
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 28, 2026, 6:27 AM EDT
Completed Not applicable Interventional

Decision Support Interventions (DESI) for Prostate Cancer Screening and Treatment - Study 2

NCT01244568
View directory record Official record
Conditions
Prostate Cancer
Interventions
Prostate cancer treatment DESI
Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
45 Years and older · Male only
Enrollment
218 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
2
States / cities
Palo Alto, California • Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 23, 2014 · Synced Oct 28, 2026, 6:27 AM EDT
Completed Phase 1 Interventional

Endoxifen in Adults With Hormone Receptor Positive Solid Tumors

NCT01273168
View directory record Official record
Conditions
Hormone Receptor-Positive Breast, Gynecologic, Desmoid, Hormone Receptor-Positive Neoplasms
Interventions
Z-Endoxifen
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2025
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 23, 2025 · Synced Oct 28, 2026, 6:27 AM EDT
Recruiting Early Phase 1 Interventional

Adjuvant Therapy Based on Pathologic Response After Neoadjuvant Encorafenib Binimetinib in Melanoma

NCT04741997
View directory record Official record
Conditions
Melanoma Stage III, Melanoma Stage IV, BRAF V600 Mutation
Interventions
Encorafenib Pill, Binimetinib Pill, Nivolumab
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 28, 2026, 6:27 AM EDT
Completed Phase 1 Interventional

ARQ 501 in Combination With Docetaxel in Patients With Cancer

NCT00099190
View directory record Official record
Conditions
Carcinoma
Interventions
ARQ 501
Drug
Lead sponsor
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Apr 28, 2009 · Synced Oct 28, 2026, 6:27 AM EDT